Clinical trialNo phase (not a drug trial)Withdrawn
Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm
Preoperative, Specialty Palliative Care for Patients Considering Pancreatic Surgery: Pilot Feasibility and Acceptability Study
- Outcome
- Stopped earlyStudy closed before opening to accrual; Insufficient staff (Enrollment)
- Phase
- No phase (not a drug trial)
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 1 September 2025
- Planned end
- 1 January 2026
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Percentage of recruited patients that consent (acceptability); Percentage of patients randomized to the interventional arm who complete the palliative care consult prior to tumor board (feasibility)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 29 June 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This clinical trial evaluates a palliative care consultation for improving communication between providers and patients considering surgery for a pancreatic neoplasm. Pancreatic operations have known complications that can affect quality of life. Palliative care has been shown to improve patient reported quality of life and functional outcomes. Receiving a palliative care consultation may improve communication and decision making for patients considering surgery for a pancreatic neoplasm.
Detailed description public domain (ClinicalTrials.gov)
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline. ARM II: Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline. After completion of study intervention, patients are followed up 7 days after the tumor board visit and 90 days after initiation of treatment.